Arisaph Pharmaceuticals, Inc. is an emerging biopharmaceutical company focused on developing novel therapies for cardiometabolic diseases and cancer. The company utilizes proprietary drug discovery platforms to develop differentiated medicines that are highly potent and act selectively on validated targets. Arisaph currently has several active drug discovery programs in various stages of development.
Arisaph employs rational drug design approaches to develop differentiated new chemical entities (NCEs) that are highly potent and act on select, validated targets. By focusing its drug development activities on validated targets, the Company believes that the risks associated with new chemical entity development can be mitigated compared with developing first-in-class compounds for nonvalidated targets.
Arisaph was co-founded by Dr. William Bachovchin (Professor of Biochemistry at Tufts University Medical School), Christopher Kiritsy (former EVP Corporate Development and CFO of Kos Pharmaceuticals, Inc.) and Michael Jaharis (Principal founder of Kos and former CEO of Key Pharmaceuticals). Kos, which was acquired by Abbott Laboratories for approximately $4 billion in 2006, was a highly successful fully-integrated pharmaceutical company that pioneered the development of HDL cholesterol therapies with the advent of Niaspan®. Similar to Kos, the vision of Arisaph is to become a fully-integrated biopharmaceutical company, in which Arisaph not only develops its differentiated therapies, but also commercializes such products through a specialty sales force.